Suman Pandey
Overview
Explore the profile of Suman Pandey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ferreira S, Pandey S, Hemminger J, Bozdag S, Antunes M
PLoS One
. 2025 Feb;
20(2):e0318532.
PMID: 39913369
Plants respond to biotic stressors by modulating various processes in an attempt to limit the attack by a pathogen or herbivore. Triggering these different defense processes requires orchestration of a...
2.
Ferreira S, Pandey S, Hemminger J, Bozdag S, Antunes M
bioRxiv
. 2024 Aug;
PMID: 39149262
Plants respond to biotic stressors by modulating various processes in an attempt to limit the attack by a pathogen or herbivore. Triggering these different defense processes requires orchestration of a...
3.
Mittal N, Kumar S, Rajmani R, Singh R, Lemoine C, Jakob V, et al.
NPJ Vaccines
. 2023 Oct;
8(1):161.
PMID: 37880298
With the rapid emergence of variants of concern (VOC), the efficacy of currently licensed vaccines has reduced drastically. VOC mutations largely occur in the S1 subunit of Spike. The S2...
4.
Madugula S, Pandey S, Amalapurapu S, Bozdag S
ACS Omega
. 2023 Jun;
8(23):20379-20388.
PMID: 37323377
The nuclear receptor (NR) superfamily includes phylogenetically related ligand-activated proteins, which play a key role in various cellular activities. NR proteins are subdivided into seven subfamilies based on their function,...
5.
Khaleeq S, Sengupta N, Kumar S, Patel U, Rajmani R, Reddy P, et al.
Viruses
. 2023 Feb;
15(2).
PMID: 36851560
Rapid emergence of the SARS-CoV-2 variants has dampened the protective efficacy of existing authorized vaccines. Nanoparticle platforms offer a means to improve vaccine immunogenicity by presenting multiple copies of desired...
6.
Kar U, Khaleeq S, Garg P, Bhat M, Reddy P, Vignesh V, et al.
Front Immunol
. 2022 Jun;
13:890622.
PMID: 35720346
Current influenza vaccines need to be updated annually due to mutations in the globular head of the viral surface protein, hemagglutinin (HA). To address this, vaccine candidates have been designed...
7.
van Vuren P, McAuley A, Kuiper M, Singanallur N, Bruce M, Riddell S, et al.
Viruses
. 2022 Apr;
14(4).
PMID: 35458530
As existing vaccines fail to completely prevent COVID-19 infections or community transmission, there is an unmet need for vaccines that can better combat SARS-CoV-2 variants of concern (VOC). We previously...
8.
Ahmed S, Khan M, Gayathri S, Singh R, Kumar S, Patel U, et al.
Front Immunol
. 2021 Dec;
12:765211.
PMID: 34956193
Saturation suppressor mutagenesis was used to generate thermostable mutants of the SARS-CoV-2 spike receptor-binding domain (RBD). A triple mutant with an increase in thermal melting temperature of ~7°C with respect...
9.
Malladi S, Patel U, Rajmani R, Singh R, Pandey S, Kumar S, et al.
ACS Infect Dis
. 2021 Jul;
7(8):2546-2564.
PMID: 34260218
The receptor binding domain (RBD) of SARS-CoV-2 is the primary target of neutralizing antibodies. We designed a trimeric, highly thermotolerant glycan engineered RBD by fusion to a heterologous, poorly immunogenic...
10.
Pramanick I, Sengupta N, Mishra S, Pandey S, Girish N, Das A, et al.
Structure
. 2021 May;
29(8):834-845.e5.
PMID: 33932324
Spike (S) glycoprotein of SARS-CoV2 exists chiefly in two conformations, open and closed. Most previous structural studies on S protein have been conducted at pH 8.0, but knowledge of the...